SAN DIEGO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of Canadian Patent No. 2,365,416 and Japanese Patent No. 4,800,485 covering Vical’s novel cationic lipid/co-lipid adjuvant, Vaxfectin®. Specific claims include composition of the Vaxfectin® adjuvant, composition of Vaxfectin®-formulated vaccines, and methods for their use. The new patents add to Vical’s existing U.S. and European patent coverage for Vaxfectin® and to Vical’s family of core technology patents broadly covering gene-based vaccines and therapeutics.
